Key facts
- Antarka’s last known valuation is $6.0M (Dec 2025).
- It has raised $4.5M; the latest was Seed Round ($3.5M) in Feb 2026.
- Notable investors include SOSV, IndieBio, Grid Exponential, AIR Capital, Vox Capital — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Antarka
- ·The full record, as it builds
Funding rounds
No funding rounds for Antarka are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Antarka
Developer of a biotechnology platform designed to repair UV-induced DNA damage in skin cells for skin longevity. The company's platform offers skin-permeable DNA-repair enzymes derived from Antarctic extremophile microorganisms with scalable purity for topical use, enabling cosmetic and skincare formulators to integrate ingredients that address photoaging with validated safety and efficacy.
- Sector
- Healthcare
- HQ
- Montevideo, Uruguay
- Founded
- 2023
- Employees
- 4
- Website
- antarka.bio/
- Ownership
- Privately Held (backing)
Antarka doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Antarka shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Antarka in its N-PORT filings yet. We sweep new filings monthly.